Skip to main content
INBX logo
INBX
(NASDAQ)
Inhibrx Biosciences, Inc.
$63.53-- (--)
Loading... - Market loading

Inhibrx Biosciences (INBX) Key Statistics & Financial Metrics

Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.

Stock Valuation Metrics

Market value, earnings multiples, and pricing ratios

Market Valuation & Earnings Multiples

Market capitalization, P/E ratios, and enterprise value

Market Cap983.32M
Enterprise Value986.88M

Price-Based Ratios

Valuation ratios based on stock price

Price/Sales (ttm)741.29
Forward Price/Sales918.14
Price/Book (mrq)28.18
Price/Tangible Book (mrq)28.18

Enterprise Value Ratios

EV-based valuation multiples

EV/Revenue704.91
EV/Earnings-6.36
EV/EBITDA-6.88
EV/EBIT-6.76
EV/FCF-6.88

Stock Price

Current price, 52-week range, and moving averages

Current Price$63.53
1-Day Change-0.27%
52-Week High$94.57
52-Week Low$10.81
52-Week Change377.22%
YTD Change-10.65%
1-Year Change375.53%
50-Day MA$73.95
200-Day MA$53.38
Avg Volume (30 day)190.00K

Share Statistics

Outstanding shares, float, and per-share metrics

Shares Outstanding15.48M
Book Value per Share$2.38
Net Cash per Share$9.75
FCF per Share$-9.27

Profitability & Financial Performance

Profit margins, return metrics, and earnings analysis

Profit Margins

Profitability margins across income statement

Gross Margin-86.29%
EBITDA Margin (ttm)-10247.50%
EBIT Margin (ttm)-10433.79%
Operating Margin (ttm)-11002.14%
Pretax Margin (ttm)-11077.43%
Profit Margin (ttm)-11077.57%
FCF Margin (ttm)-10245.64%

Return on Investment Metrics

ROE, ROA, ROIC, and capital efficiency ratios

Return on Equity (ttm)-421.09%
Return on Assets (ttm)-87.39%
Return on Capital Employed (ttm)-103.24%

Income Statement (TTM)

Trailing twelve months revenue and earnings

Revenue1.40M
Gross Profit-1.21M
Operating Income-154.03M
Pretax Income-155.08M
Net Income-155.09M
EBITDA-143.47M
EBIT-146.07M
Diluted EPS$-10.02

Cash Flow (TTM)

Operating cash flow and free cash flow metrics

Operating Cash Flow-143.39M
Capital Expenditures47.00K
Free Cash Flow-143.44M

Growth Rates (YoY)

Year-over-year growth metrics

Dividend Growth-100.00%

Financial Health & Dividends

Balance sheet analysis, debt ratios, and dividend metrics

Assets & Cash

Total assets and cash positions

Total Assets (mrq)177.47M
Cash & Securities (mrq)153.09M
Net Cash (mrq)150.84M
Net Cash per Share$9.75

Debt & Liabilities

Liabilities, debt, equity, and working capital

Total Debt (mrq)102.16M
Working Capital (mrq)125.44M
Total Equity (mrq)36.83M
Book Value per Share$2.38

Liquidity & Leverage

Liquidity, leverage, and debt coverage ratios

Current Ratio (mrq)4.49
Quick Ratio (mrq)4.49
Debt/Equity (mrq)2.77

Dividend History & Payout Analysis

Dividend yield, payout ratios, and growth metrics

Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Dividend Growth (YoY)-100.00%
Ex-Dividend DateMay 30, 2024
Pay DateJun 20, 2024

Yield Metrics

Earnings, FCF, buyback, and shareholder yields

Earnings Yield-14.94%
FCF Yield-13.82%
Buyback Yield0.00%
Total Shareholder Yield0.00%

Financial Health Scores

Risk assessment and quality metrics

Altman Z-Score0.88
Piotroski F-Score3/9

Frequently Asked Questions About Inhibrx Biosciences Statistics

What are the key financial metrics for INBX?

Inhibrx Biosciences, Inc. (INBX) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.

What is INBX's valuation analysis?

The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Inhibrx Biosciences is overvalued or undervalued.

How do I read INBX's profitability ratios?

Inhibrx Biosciences's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.

What do INBX's debt ratios indicate?

The financial health section shows Inhibrx Biosciences's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.

What is INBX's dividend analysis?

The dividend section covers Inhibrx Biosciences's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.